ORG-34517

DB05423InvestigationalSmall molecule

ORG-34517 is currently under investigation by Organon for the treatment of depression. It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in...

Mechanism: Org-34517 is a glucocorticoid antagonist which may have a potential in a number of diseases where there is excess corticosterone/cortisol activity. The drug acts by normalizing hyperactivity in the hypothalamus-pituitary-adrenal (HPA) axis.
Curator reviewed
Primary indication: Investigated for use/treatment in depression.Curator reviewed
Formula / weight: C₂₈H₃₀O₄ · 430.544 g/mol (avg)
Code names: ORG-34517

Resolves to

Compound

UNII17VAN37K4YCAS189035-07-2PubChem9867361

Structure

InChIKeyDFELGYQKEOCHOA-BZAFBGKRSA-NSMILES[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C3OCOC3=C1)C1=C3CCC(=O)C=C3CC[C@@]21[H]

Targets

P04150NR3C1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with ORG-34517, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account